# Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

> **NCT03013998** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beat AML, LLC** · enrollment: 3000 (estimated)

## Conditions studied

- Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** Samalizumab (BAML-16-001-S1)
- **BIOLOGICAL:** BI 836858 (BAML-16-001-S2)
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Daunorubicin (BAML-16-001-S1)
- **DRUG:** Cytarabine (BAML-16-001-S1)
- **DRUG:** Azacitidine (BAML-16-001-S2)
- **DRUG:** AG-221 (BAML-16-001-S3)
- **DRUG:** Azacitidine (BAML-16-001-S3)
- **DRUG:** Entospletinib (BAML-16-001-S4)
- **DRUG:** Azacitidine (BAML-16-001-S4)
- **DRUG:** Entospletinib (BAML-16-001-S5)
- **DRUG:** Decitabine (BAML-16-001-S5)
- **DRUG:** Entospletinib (BAML-16-001-S6)
- **DRUG:** Daunorubicin (BAML-16-001-S6)
- **DRUG:** Cytarabine (BAML-16-001-S6)
- **DRUG:** Pevonedistat (BAML-16-001-S9)
- **DRUG:** Azacitidine (BAML-16-001-S9)
- **DRUG:** AG-120 (BAML-16-001-S16)
- **DRUG:** Azacitidine (BAML-16-001-S16)
- **DRUG:** Gilteritinib (BAML-16-001-S8 Group 1)

## Key facts

- **NCT ID:** NCT03013998
- **Lead sponsor:** Beat AML, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-11
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03013998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03013998, "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03013998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*